Dealbreaker on MSN1d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
Fierce Biotech2d
Beam gene therapy for protein deficiency passes early safety test, sets efficacy bar in space: analyst
The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...
ICS Learn10d
Accounting Jobs at AAT Level 2, 3 and 4
Thinking of pursuing an accounting qualification? We explore the different roles you could be qualified for after completing ...
Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition
The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...
BioSpace1d
Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD
BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.
BioPharma Dive2d
Beam base editing therapy gets ‘proof of concept’ in rare lung disease
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
pharmaphorum2d
Beam launches $500m financing on base-editing trial data
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.
ICS Learn9d
Accounting Jobs at Level 2, 3 and 4
The Association of Accounting Technicians (AAT) is a globally recognised body that provides industry-leading qualifications ...